Despite novel treatments, such as sodium glucose transporter 2 (SGLT2) inhibitors and glucagon-like-peptide-1 (GLP-1) receptor agonists, the fraction of patients with well-controlled diabetes has not risen appreciably [16]. Here, GLP1R is linked to diabetes mellitus.